Related references
Note: Only part of the references are listed.Performance of Long-Term CT and PET/CT Surveillance for Detection of Distant Recurrence in Patients with Resected Stage IIIA-D Melanoma
Robin M. Turner et al.
ANNALS OF SURGICAL ONCOLOGY (2021)
Whole-Body [18F]FDG-PET/MRI vs. [18F]FDG-PET/CT in Malignant Melanoma
Dominik Berzaczy et al.
MOLECULAR IMAGING AND BIOLOGY (2020)
Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti-PD-1 therapy
Ines Pires da Silva et al.
CANCER (2020)
Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
O. Hamid et al.
ANNALS OF ONCOLOGY (2019)
Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma
Y. J. L. Jansen et al.
ANNALS OF ONCOLOGY (2019)
Susceptibility-weighted imaging in malignant melanoma brain metastasis
Daniel Schwarz et al.
JOURNAL OF MAGNETIC RESONANCE IMAGING (2019)
Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm
Neta Tsur et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2019)
Follow-Up Recommendations after Diagnosis of Primary Cutaneous Melanoma: A Population-Based Study in New South Wales, Australia
Rebecca L. Read et al.
ANNALS OF SURGICAL ONCOLOGY (2018)
Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab
Richard W. Joseph et al.
CLINICAL CANCER RESEARCH (2018)
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Hussein A. Tawbi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
J. Weber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
G. V. Long et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Whole-Body MRI: Current Applications in Oncology
Mario Morone et al.
AMERICAN JOURNAL OF ROENTGENOLOGY (2017)
Accuracy of Whole-Body DWI for Metastases Screening in a Diverse Group of Malignancies: Comparison With Conventional Cross-Sectional Imaging and Nuclear Scintigraphy
Samir Mustaffa Paruthikunnan et al.
AMERICAN JOURNAL OF ROENTGENOLOGY (2017)
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
G. V. Long et al.
ANNALS OF ONCOLOGY (2017)
Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma
Adil I. Daud et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
The updated Swiss guidelines 2016 for the treatment and follow-up of cutaneous melanoma
Reinhard Dummer et al.
SWISS MEDICAL WEEKLY (2016)
Long-Term Follow-up Results of the DANTE Trial, a Randomized Study of Lung Cancer Screening with Spiral Computed Tomography
Maurizio Infante et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Suzanne L. Topalian et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Whole-body MRI with diffusion-weighted sequences compared with 18 FDG PET-CT, CT and superficial lymph node ultrasonography in the staging of advanced cutaneous melanoma: a prospective study
J. C. Jouvet et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2014)
Inter- and Intra-Patient Heterogeneity of Response and Progression to Targeted Therapy in Metastatic Melanoma
Alexander M. Menzies et al.
PLOS ONE (2014)
Whole-body diffusion-weighted imaging: is it all we need for detecting metastases in melanoma patients?
Giuseppe Petralia et al.
EUROPEAN RADIOLOGY (2013)
S3-Guideline Diagnosis, therapy and follow-up of melanoma - short version
Annette Pflugfelder et al.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT (2013)
Predictors and survival in patients with melanoma brain metastases
Ugo Bottoni et al.
MEDICAL ONCOLOGY (2013)
Whole-body MRI including diffusion-weighted imaging compared to CT for staging of malignant melanoma
Firas Mosavi et al.
UPSALA JOURNAL OF MEDICAL SCIENCES (2013)
Site and Timing of First Relapse in Stage III Melanoma Patients: Implications for Follow-Up Guidelines
Emanuela Romano et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Radiation Risk From Medical Imaging
Eugene C. Lin
MAYO CLINIC PROCEEDINGS (2010)
The Danish Randomized Lung Cancer CT Screening Trial-Overall Design and Results of the Prevalence Round
Jesper H. Pedersen et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
Diffusion-weighted whole-body MR screening
Joan C. Vilanova et al.
EUROPEAN JOURNAL OF RADIOLOGY (2008)
Generating statements at whole-body imaging with a workflow-optimized software tool -: First experiences with multireader analysis
C. Mueller-Horvat et al.
ROFO-FORTSCHRITTE AUF DEM GEBIET DER RONTGENSTRAHLEN UND DER BILDGEBENDEN VERFAHREN (2007)
The conundrum of follow-up: Should it be abandoned?
Omgo E. Nieweg et al.
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA (2006)
Prospective comparison of the impact on treatment decisions of whole-body magnetic resonance imaging and computed tomography in patients with metastatic malignant melanoma
C Müller-Horvat et al.
EUROPEAN JOURNAL OF CANCER (2006)
Follow-up in patients with localised primary cutaneous melanoma
AB Francken et al.
LANCET ONCOLOGY (2005)
Share Paper
